Primary Bile Duct Melanoma Causing Obstructive Jaundice

Naga S. Addepally, MBBS1, Jagpal S. Clair, MBBS1, Keith Lai, MD3, Farshad Aduli, MD1,2, and Mohit Girotra, MD, FACP1,2

1Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR
2Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR
3Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR

ABSTRACT
Malignant melanoma is one of the few malignancies that are well known for unusual behavior. Primary malignant melanoma usually originates from squamous epithelium of skin, mucous membranes, retina, and uvea. Although melanoma can metastasize to any part of the body, including the biliary tract, primary malignant melanoma of bile ducts is an extremely rare entity. We present a 52-year-old man who presented with 5-month epigastric pain and 15-pound weight loss, with 1-week duration of jaundice, nausea/vomiting, pale stools, and dark urine, blood work suggested cholestatic jaundice. Imaging revealed a large perihilar/peripancreatic mass involving the portal vein and hepatic artery, and intrahepatic biliary dilation. Biliary brushings revealed neoplastic cells strongly suggestive of malignant melanoma.

INTRODUCTION
Malignant melanoma is one of the few malignancies that are well known for unusual behavior. Primary malignant melanoma (PMM) usually originates from squamous epithelium of skin, mucous membranes, retina, and uvea. Although melanoma can metastasize to any part of the body, including the biliary tract, PMM of bile ducts (PMM-BD) is an extremely rare entity.

CASE PRESENTATION
A 52-year-old man with history of diabetes, multiinfarct dementia, and polysubstance abuse presented with 1-week history of jaundice, pale stools, nausea, and vomiting. He also reported associated 5-month history of abdominal pain radiating to the back, right side of chest, and shoulder, associated with decreased appetite and weight loss of over 15 pounds. Patient was thin and cachectic, with scleral icterus, mild epigastric tenderness without distension, and normal cardiopulmonary exam. Laboratory workup revealed mild anemia (hemoglobin, 10.1 g/dL), hepatic panel in cholestatic pattern (alkaline phosphatase, 711 IU/L; AST, 86 IU/L; ALT, 96 IU/L; and total bilirubin 20.9, mg/dL). Abdominal computed tomography with contrast revealed a perihilar mass involving portal vein and hepatic artery (Figure 1). Due to vascular involvement, he was deemed unsuitable candidate for surgical intervention by surgical oncology. He was referred to gastrointestinal (GI) service for tissue acquisition and palliative biliary management.

Endoscopic retrograde cholangiopancreatography suggested narrowing at the level of common hepatic duct (CHD) with intrahepatic biliary dilation but normal appearing distal common bile duct (Figure 2). Endoscopic ultrasound did not reveal the mass to be arising from pancreas but rather from the perihilar area. Biliary brushings, biopsy of CHD, and fine needle aspiration (FNA) of perihilar tissue were performed, and a 8-mm to 6-cm uncovered metal stent was placed to relieve biliary obstruction. Fine needle aspiration showed neoplastic biliary ductal cells with eccentric and pleomorphic nuclei, intracytoplasmic pigment deposition, and strongly positivity for S-100 and MART staining, thus confirming diagnosis of malignant melanoma (Figure 3).
Extensive physical examination did not reveal any cutaneous, scalp, or mucosal lesions suggestive of melanoma. Fundoscopy did not show any intraocular, retinal, or uvea lesions suggestive of melanoma. Patient denied having any prior sunburns, prolonged exposure to the sun, atypical moles, or excised skin cancer. He did not have family history of any skin cancers. Colonoscopy also failed to show any mucosal lesions suggestive of melanoma. A whole-body positron emission tomography was performed 2 months later that showed spread of melanoma to sub- and supradiaphragmatic lymph nodes, liver, and mesentery. Patient was not deemed a candidate for ipilimumab due to poor performance status, and he declined chemotherapy. Few weeks later, he was diagnosed with brain metastases and was offered whole-brain radiation, but he chose to be comfort care and passed away.

**DISCUSSION**

Melanocytes are derived from the neural crest, which is part of the ectoderm, and migrate throughout the body. Malignant melanoma originates from tissues/organs derived from squamous epithelium, most commonly from skin, but also less commonly from uvea, retina, mucous membranes, and leptomeninges. Very recently, melanocytes have been understood to be present in normal human gallbladder, hence theoretically making it possible for melanomas to arise from endodermal regions of the GI tract, including mucous membranes of mouth, esophagus, lower colon, and anus. Primary malignant melanoma of GI tract is a rather rare entity, only 24 cases of PMM-gallbladder and 12 cases of PMM-BD were reported thus far, and is hence very poorly understood by practicing gastroenterologists. In addition, a handful of primary ampullary melanoma cases are reported. It is observed that the majority of melanomas of the bile duct represent metastases from a cutaneous source and tend to present as multiple, flat pigmented lesions, whereas primary lesion manifests as a single pedunculated polypoid mass in the lumen of duct. Our case was novel, because it manifested as perihilar mass with CHD narrowing, which is not reported in literature thus far.

Different publications have focused on potential criteria to differentiate between primary and secondary melanomas, including exclusion of previous history of primary melanoma, absence of synchronous involvement of sites other than the considered one, unicity of the lesion, polypoid or papillary shape, and presence of a junctional activity at the tumor site, as proposed by Ricci et al in 2001. However, these criteria are very weak if each is considered singularly. Hence, a thorough physical examination is essential to exclude alternative sites of melanoma origin, including dermatology evaluation for naevi (both skin and scalp), mucosal exam (buccal, upper

---

*Figure 1.* Abdominal computed tomography showing a perihilar mass.

*Figure 2.* Cholangiogram showing intrahepatic biliary dilation (A) and narrowing at the level of CHD (B) with normal appearing distal common bile duct.
with bile duct resection, hepatic lobectomy, with or without en-
surgically managed (with Whipple procedure or cholecystectomy
resected specimen, for histochemical staining and precise diag-
brush or biopsy or endoscopic ultrasound-FNA, or rarely
key, with endoscopic retrograde cholangiopancreatography
high-intensity signal on MRI.12 Ultimately, tissue acquisition is the
Presence of melanosomes in the tumor can occasionally provide
obstruction and exclude pancreatic/ampullary pathologies.
computed tomography, or MRI/MRCP to demonstrate biliary
employ several diagnostic modalities, including ultrasonogram,
Diagnosis of PMM-BD needs a high index of suspicion and may
pain/discomfort,9,13,19 diffuse pruritus,15 and acute cholecystitis.11
patients), as was the case with our patient, followed by abdominal
in 7/12 patients), as was the case with our patient, followed by abdominal
The most common presentation is cholestatic jaundice (in 7/12
Diffuse melanoma: 54 cases and review of the literature. Virchows Arch 2000;357(4):427–432.
A case report and review of the literature. Arch Pathol Lab Med 1991;115:915–917.
Malignant melanoma of the hepatic and common bile ducts. A case report and review of the litera-
Deugnier Y, Turlin B, Lehry D, et al. Malignant melanoma of the hepatic duct: A case report.
Ricci R, Maggiano N, Martini M, et al. Primary malignant melanoma of the biliary tract.
Bejarano González N, García Moforte N, Darnell Martín A, et al. Primary malignant melanoma of the common bile duct: A case report and review of the literature. Arch Pathol Lab Med 2000;124:419–422.
Medina V, Darnell A, Bejarano N, et al. Primary biliary tract melanoma: A case report and review of the literature. Abdom Imaging 2006;31:64–69.
Smith NE, Taube JM, Warczynski TM, Collier KD, Pawlik TM. Primary biliary tract melanoma: Report of a case and review of the literature. Int J Surg Case Rep 2012;3(9):441–444.
Wright RA, Brewer M. Primary malignant melanoma of the common bile duct. South Med J 1988;81:396–402.
Washburn WK, Noda S, Lewis WD, et al. Primary malignant melanoma of the biliary tract. Liver Transpl Surg 1995;1(2):103–106.
Ricci R, Maggiano N, Martini M, et al. Primary malignant melanoma of the gallbladder in dysplastic naevus syndrome. Virchows Archiv 2001;438(2):159–165.
Agrawal D, Tannous GC, Chak A. Primary malignant melanoma of the hepatic duct: A case report. Gastrointest Endosc 2010;72(4):845–846.

DISCLOSURES
Author contributions: NS Addepally and JS Klair searched literature and prepared the manuscript. K. Lai provided pathology pictures. M. Girotra and F. Aduli supervised the manuscript preparation and are the article guarantors.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Received November 25, 2015; Accepted March 31, 2016

REFERENCES
1. Le Douarin NM. Cell migrations in embryos. Cell. 1984;38(2):353–360.
2. Peison B, Rabin L. Malignant melanoma of the gallbladder: Report of three cases and review of the literature. Cancer. 1976;37(5):2448–2454.
3. Verbank JJ, Rutgeerts L.J, van Aelst F.J, et al. Primary malignant melanoma of the gallbladder, metastatic to the common bile duct. Gastroenterology. 1986;91(2):214–219.
4. Zhang ZD, Myles J, Pai RP, et al. Malignant melanoma of the biliary tract: A case report. Surgery. 1991;109:323–328.
5. Heath DI, Womack C. Primary malignant melanoma of the gall bladder. J Clin Pathol. 1988;41:1073–1077.
6. Mărgăritescu I, Chiriţă A.D, Vasilescu F. Completely regressed primary cutaneous melanoma - difficulties in diagnosis and classification. Rom K Morphol Embryol. 2014;55(2 Suppl):635–642.
7. Zaide EC. Malignant melanoma of cholecodochus. Arq Oncol. 1963;5:254–5.
8. Carstens HB, Ghazi C, Carnighan RH, Brewer MS. Primary malignant melanoma of the common bile duct. Hum Pathol. 1986;17:1282–1285.
9. Deugnier Y, Turlin B, Lehry D, et al. Malignant melanoma of the hepatic and common bile ducts. A case report and review of the literature. Arch Pathol Lab Med. 1991;115:915–917.
10. Gates J, Kane RA, Hartnell GG. Primary biliary tract malignant melanoma. Abdom Imaging. 1996;21(5):453.
11. Wagner MS, Shoup M, Pickleman J, et al. Primary malignant melanoma of the common bile duct: A case report and review of the literature. Arch Pathol Lab Med. 2000;124:419–422.
12. Medina V, Darnell A, Bejarano N, et al. Primary biliary tract melanoma: US, CT and MR findings. 2003;28(6):842–846.
13. Bejarano González N, García Molforte N, Darnell Martín A, et al. Primary malignant melanoma of the common bile duct. A case report and literature review. Gastroenterol Hepatol. 2005;28(7):382–384.
14. Hoshi K, Saithoh Y, Anzai R, Tanno H. A case of primary malignant melanoma of the bile duct. Nihon Shokaki Geka Gakkai Zasshi. 2006;59:317–322.
15. Smith NE, Taube JM, Warczynski TM, Collier KD, Pawlik TM. Primary biliary tract melanoma: Report of a case and review of the literature. Int J Surg Case Rep. 2012;5(9):441–444.
16. Wright RA, Brewer M. Primary malignant melanoma of the common bile duct. South Med J 1988;81:396–402.
17. Washburn WK, Noda S, Lewis WD, et al. Primary malignant melanoma of the biliary tract. Liver Transpl Surg 1995;1(2):103–106.
18. Ricci R, Maggiano N, Martini M, et al. Primary malignant melanoma of the gallbladder in dysplastic naevus syndrome. Virchows Archiv 2001;438(2):159–165.
19. Agrawal D, Tannous GC, Chak A. Primary malignant melanoma of the hepatic duct: A case report. Gastrointest Endosc 2010;72(4):845–846.

Figure 3. (A) Smear of FNA specimen from bile duct showing pleomorphic malignant cells with enlarged nuclei and multiple nucleoli. (B) H&E stain 200x magnification showing pleomorphic malignant cells, some with pigmentation and atypical mitotic figures. These tumor cells are strongly and diffusely positive for S-100 and MART-1 stains as below. (C) Tumor cells showing positive staining for S-100. (D) Tumor cells showing positive stain for MART stain.